79 related articles for article (PubMed ID: 20547082)
1. Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats.
Yang Y; Dahly-Vernon AJ; Blomme EA; Lai-Zhang J; Kempf DJ; Marsh KC; Harrington YA; Nye SH; Evans DL; Roman RJ; Jacob HJ; Waring JF
Vet J; 2010 Jul; 185(1):75-82. PubMed ID: 20547082
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.
Lum PY; He YD; Slatter JG; Waring JF; Zelinsky N; Cavet G; Dai X; Fong O; Gum R; Jin L; Adamson GE; Roberts CJ; Olsen DB; Hazuda DJ; Ulrich RG
Genomics; 2007 Oct; 90(4):464-73. PubMed ID: 17719200
[TBL] [Abstract][Full Text] [Related]
3. Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats.
Mak IT; Kramer JH; Chen X; Chmielinska JJ; Spurney CF; Weglicki WB
Am J Physiol Regul Integr Comp Physiol; 2013 Nov; 305(10):R1102-11. PubMed ID: 24049113
[TBL] [Abstract][Full Text] [Related]
4. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.
Shafran SD; Mashinter LD; Roberts SE
HIV Med; 2005 Nov; 6(6):421-5. PubMed ID: 16268824
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Xu A; Yin S; Wong L; Chan KW; Lam KS
Endocrinology; 2004 Feb; 145(2):487-94. PubMed ID: 14592951
[TBL] [Abstract][Full Text] [Related]
6. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
7. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.
Zhou H; Gurley EC; Jarujaron S; Ding H; Fang Y; Xu Z; Pandak WM; Hylemon PB
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1071-80. PubMed ID: 16861219
[TBL] [Abstract][Full Text] [Related]
8. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Waring JF; Ciurlionis R; Marsh K; Klein LL; Degoey DA; Randolph JT; Spear B; Kempf DJ
Arch Toxicol; 2010 Apr; 84(4):263-70. PubMed ID: 20213465
[TBL] [Abstract][Full Text] [Related]
9. Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
Cao R; Hu Y; Wang Y; Gurley EC; Studer EJ; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Zhou H
J Pharmacol Exp Ther; 2010 Aug; 334(2):530-9. PubMed ID: 20472667
[TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Lenhard JM; Croom DK; Weiel JE; Winegar DA
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2625-9. PubMed ID: 11116063
[TBL] [Abstract][Full Text] [Related]
11. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
[TBL] [Abstract][Full Text] [Related]
12. Hypocholesterolemia of Rhizoma Coptidis alkaloids is related to the bile acid by up-regulated CYP7A1 in hyperlipidemic rats.
Cao Y; Bei W; Hu Y; Cao L; Huang L; Wang L; Luo D; Chen Y; Yao X; He W; Liu X; Guo J
Phytomedicine; 2012 Jun; 19(8-9):686-92. PubMed ID: 22554715
[TBL] [Abstract][Full Text] [Related]
13. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
14. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.
Brown CA; Lesher JL; Peterson CM
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S86-9. PubMed ID: 15858517
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.
Lei B; Zha W; Wang Y; Wen C; Studer EJ; Wang X; Jin F; Wang G; Zhang L; Zhou H
Mol Pharm; 2010 Jun; 7(3):844-53. PubMed ID: 20349948
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia associated with protease inhibitor therapy.
Echevarria KL; Hardin TC; Smith JA
Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
Moyle GJ
AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
[No Abstract] [Full Text] [Related]
18. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.
Lee GA; Rao MN; Grunfeld C
Curr HIV/AIDS Rep; 2005 Feb; 2(1):39-50. PubMed ID: 16091248
[TBL] [Abstract][Full Text] [Related]
19. Cooked rice prevents hyperlipidemia in hamsters fed a high-fat/cholesterol diet by the regulation of the expression of hepatic genes involved in lipid metabolism.
Choi WH; Gwon SY; Ahn J; Jung CH; Ha TY
Nutr Res; 2013 Jul; 33(7):572-9. PubMed ID: 23827132
[TBL] [Abstract][Full Text] [Related]
20. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
